专题笔谈

循环肿瘤DNA检测在人乳头瘤病毒相关性宫颈癌中的应用与展望

  • 江宝妮 ,
  • 张美琴 ,
  • 杨露 ,
  • 陈致远 ,
  • 韩娜娜
展开
  • 南方医科大学珠江医院妇产医学中心 (广州 510280 )
韩娜娜,教授,现任南方医科大学珠江医院妇产科副主任医师,医学硕士,硕士研究生导师,广东省精准医学应用学会妇科肿瘤分会副主任委员、广东省基层医药学会妇科专业委员会副主任委员、中国医疗保健国际交流促进会妇产医学分会委员、中华预防医学会生殖健康分会妇科肿瘤学组成员、广东省医学会妇产科学分会第十三届青委会常务委员、广东省医学会妇科肿瘤学分会第一届委员会委员、广东省健康管理学会妇科肿瘤多学科协作专业委员会委员、广东省医学会计划生育学分会委员、广东省中西医结合妇科分会委员。从事妇科学临床、教学与科研工作15年,主要研究方向为妇科良恶性肿瘤的腹腔镜手术治疗和妇科恶性肿瘤综合治疗。近5年,发表妇科相关的专业论文十余篇(其中3篇SCI,8篇北图核心,均为第一作者),参编专著1部,主持省级课题2项、校级课题1项,参加国家及省级课题6项。E-mail:hannana0126@126.com

收稿日期: 2023-06-06

  网络出版日期: 2024-03-06

基金资助

国家自然科学基金青年科学基金项目(82001501)

Application and prospects of ctDNA detection in HPV associated cervical cancer

  • Baoni JIANG ,
  • Meiqin ZHANG ,
  • Lu YANG ,
  • Zhiyuan CHEN ,
  • Na′na HAN
Expand
  • Obstetrics and Gynecology Medical Center of the Zhujiang Hospital of Southern Medical University,Guangzhou 510280,China

Received date: 2023-06-06

  Online published: 2024-03-06

摘要

循环肿瘤DNA(circulating tumor DNA, ctDNA)是直接来源于肿瘤的无细胞状态DNA,其常携带全面的肿瘤基因信息;研究发现ctDNA的检测可在肿瘤的早期诊断、靶向治疗以及预测复发中发挥作用;人乳头瘤病毒(human papilloma virus, HPV)相关性妇科恶性肿瘤主要包括大部分宫颈癌、部分外阴癌及阴道癌,高危型HPV长期感染以及与细胞基因组的整合为这些癌肿重要的致病原因,研究发现利用ctDNA检测技术动态检测HPV-ctDNA的变化则可以为这些肿瘤的临床管理以及预后提供有价值的信息。因此,HPV-ctDNA有望成为HPV相关肿瘤的重要生物标志物。

本文引用格式

江宝妮 , 张美琴 , 杨露 , 陈致远 , 韩娜娜 . 循环肿瘤DNA检测在人乳头瘤病毒相关性宫颈癌中的应用与展望[J]. 实用医学杂志, 2024 , 40(2) : 129 -132 . DOI: 10.3969/j.issn.1006-5725.2024.02.001

Abstract

Circulating tumor DNA (ctDNA) is a kind of cell-free DNA derived from tumors, which carries comprehensive tumor genetic information; Recent studies have found that ctDNA detection can play a role in the early diagnosis, targeted therapy, and prediction of recurrence in tumors. Human papillomavirus (HPV)-associated gynecological malignancies include most cervical cancer, some vulvar cancer, and vaginal cancer. High-risk HPV long-term infection and integration with cell genome are important causes of these cancers. Studies found that the use of ctDNA detection technology to dynamically monitor changes in HPV-ctDNA can provide valuable information for the clinical management and prognosis of these cancers. Thus, HPV-ctDNA is expected to become an biomarker for HPV- associated tumors.

参考文献

1 KAZEMIFARD N, SADEGHI A, VARAMINIAN B, et al. Circulating tumor DNA applications in monitoring the treatment of metastatic colorectal cancer patients[J]. Gastroenterol Hepatol Bed Bench, 2019,12():S14-S21.
2 BETTEGOWDA C, SAUSEN M, LEARY R J, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies[J]. Sci Transl Med, 2014,6(224):224ra24.
3 SAAVEDRA K P, BREBI P M, ROA J C. Epigenetic alterations in preneoplastic and neoplastic lesions of the cervix[J]. Clin Epigenetics, 2012,4(1):13. doi:10.1186/1868-7083-4-13
4 中国抗癌协会妇科肿瘤专业委员会. 阴道恶性肿瘤诊断与治疗指南(2021年版)[J].中国癌症杂志, 2021,31:546-60.
5 CAMPITELLI M, JEANNOT E, PETER M, et al. Human papillomavirus mutational insertion: specific marker of circulating tumor DNA in cervical cancer patients[J]. PLoS One, 2012,7(8):e43393. doi:10.1371/journal.pone.0043393
6 CAROW K, G?LITZ M, WOLF M, et al. Viral-Cellular DNA Junctions as Molecular Markers for Assessing Intra-Tumor Heterogeneity in Cervical Cancer and for the Detection of Circulating Tumor DNA[J]. Int J Mol Sci, 2017,18(10):2032. doi:10.3390/ijms18102032
7 SIVARS L, PALSDOTTIR K, CRONA GUTERSTAM Y, et al. The current status of cell-free human papillomavirus DNA as a biomarker in cervical cancer and other HPV-associated tumors: A review[J]. Int J Cancer, 2023,152(11):2232,2242. doi:10.1002/ijc.34333
8 B?NL?KKE S, STOUGAARD M, SORENSEN B S, et al. The Diagnostic Value of Circulating Cell-Free HPV DNA in Plasma from Cervical Cancer Patients[J]. Cells, 2022,11(14):2170. doi:10.3390/cells11142170
9 SIVARS L, HELLMAN K, CRONA GUTERSTAM Y, et al. Circulating cell-free tumor human papillomavirus DNA is a promising biomarker in cervical cancer[J]. Gynecol Oncol, 2022,167(1):107-114. doi:10.1016/j.ygyno.2022.07.028
10 JEANNOT E, LATOUCHE A, BONNEAU C, et al. Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical Cancer[J]. Clin Cancer Res, 2021,27(21):5869-5877. doi:10.1158/1078-0432.ccr-21-0625
11 CABEL L, BONNEAU C, BERNARD-TESSIER A, et al. HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancer[J]. ESMO Open,2021,6(3):100154. doi:10.1016/j.esmoop.2021.100154
12 CHEUNG T H, YIM S F, YU M Y, et al. Liquid biopsy of HPV DNA in cervical cancer[J]. J Clin Virol, 2019,114:32-36. doi:10.1016/j.jcv.2019.03.005
13 辇伟奇,于津浦,袁响林,等. ctDNA高通量测序临床实践专家共识(2022年版)[J].中国癌症防治杂志, 2022,14(3):240-252.
14 SPELLMAN P T, GRAY J W. Detecting cancer by monitoring circulating tumor DNA[J]. Nat Med, 2014,20(5):474-475. doi:10.1038/nm.3564
15 FERRIER S T, TSERING T, SADEGHI N, et al. Blood and saliva-derived ctDNA is a marker of residual disease after treatment and correlates with recurrence in human papillomavirus-associated head and neck cancer[J]. Cancer Med, 2023,12(15):15777-15787. doi:10.1002/cam4.6191
16 JEANNOT E, BECETTE V, CAMPITELLI M, et al. Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus-associated invasive carcinoma[J]. J Pathol Clin Res, 2016,2(4):201-209. doi:10.1002/cjp2.47
17 BARBANY G, ARTHUR C, LIEDéN A, et al. Cell-free tumour DNA testing for early detection of cancer - a potential future tool[J]. J Intern Med, 2019,286(2):118-136. doi:10.1111/joim.12897
18 MOSS J, MAGENHEIM J, NEIMAN D, et al. Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease[J]. Nat Commun, 2018,9(1):5068. doi:10.1038/s41467-018-07466-6
19 ROSTAMI A, LAMBIE M, YU C W, et al. Senescence, Necrosis, and Apoptosis Govern Circulating Cell-free DNA Release Kinetics[J]. Cell Rep, 2020,31(13):107830. doi:10.1016/j.celrep.2020.107830
20 BROUTET N, JERONIMO J, KUMAR S, et al. Implementation research to accelerate scale-up of national screen and treat strategies towards the elimination of cervical cancer[J]. Prev Med,2022,155:106906. doi:10.1016/j.ypmed.2021.106906
21 冯同富. 宫颈癌筛查策略的变迁及思考[J]. 实用医学杂志,2022,38(15):1865-1871. doi:10.3969/j.issn.1006-5725.2022.15.004
22 缪华章, 吴云涛,朱颖贤. 2017-2019年广东省农村适龄妇女宫颈癌和乳腺癌筛查结果和成本效果分析[J]. 实用医学杂志, 2023,39(13):1709-1713. doi:10.3969/j.issn.1006-5725.2023.13.020
23 PHALLEN J, SAUSEN M, ADLEFF V, et al. Direct detection of early-stage cancers using circulating tumor DNA[J]. Sci Transl Med, 2017,9(403):eaan2415. doi:10.1126/scitranslmed.aan2415
24 GALATI L, COMBES J D, LE CALVEZ-KELM F, et al. Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping Assay[J]. Microbiol Spectr, 2022,10(2):e0148021. doi:10.1128/spectrum.01480-21
25 谢玲玲,林荣春,林仲秋. 《2021.2 NCCN外阴鳞癌临床实践指南》解读[J]. 中国实用妇科与产科杂志, 2020,36(12):1172-1176.
26 RASMUSSEN C L, SAND F L, HOFFMANN FREDERIKSEN M, et al. Does HPV status influence survival after vulvar cancer?[J]. Int J Cancer, 2018,142(6):1158-1165. doi:10.1002/ijc.31139
27 SASTRE-GARAU X, DIOP M, MARTIN F, et al. A NGS-based Blood Test For the Diagnosis of Invasive HPV-associated Carcinomas with Extensive Viral Genomic Characterization[J]. Clin Cancer Res, 2021,27(19):5307-5316. doi:10.1158/1078-0432.ccr-21-0293
文章导航

/